PegBio Co (2565.HK) Stock Price

PegBio Co Price

CLOSED
4.14
​
Market closed

The consensus 12-month price target for PegBio Co is 10.48 CNY, about 153.0% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.

PegBio Co stock price

Access this data via the Eulerpool API

PegBio Co business model & stock analysis

PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2025-05-27. The firm's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The firm's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The firm's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).

Frequently asked questions about PegBio Co

Analysts currently set an average price target of 10.48 CNY for the PegBio Co stock (median: 10.48 CNY), implying +153.0 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the PegBio Co stock: 0 recommend buying, 2 holding and 7 selling.

Converted at the current exchange rate, the PegBio Co share trades at 0.55 EUR (4.14 CNY).

The revenue cannot currently be calculated for PegBio Co.

The expected profit of PegBio Co is -147.30 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PegBio Co is currently -11.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PegBio Co stock.

The P/S cannot be calculated for PegBio Co currently.

The Eulerpool Quality Score for PegBio Co is 2/10.

The ISIN of PegBio Co is CNE100006T44. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of PegBio Co is 2565.HK. The ticker symbol is used to trade PegBio Co shares on the stock exchange.

Fair ValueTerminal
4.02 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website pegbio.com
Country
Currency
CNY
Initial public offering
May 27, 2025
ISIN
CNE100006T44
Cusip
Y6725L107
Market capitalization
1.62 B CNYSmall Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
-11.00
P/Ee 2027
-25.88
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
3.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-46.46 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-0.53 CNY
Net Debt / EBIT
—
Debt/Equity
1.92
Last updated Oct 3, 2026, 5:42 PM

PegBio Co Peer Group

All fundamentals and in-depth analysis of PegBio Co

Our stock analysis for PegBio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PegBio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.